Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.9.4357

Are there Time-period-related Differences in the Prophylactic Effects of Bacille Calmette-Guérin Intravesical Instillation Therapy in Japan?  

Okamura, Takehiko (Department of Urology, JA Aichi Anjo Kosei Hospital)
Ando, Ryosuke (Department of Urology, JA Aichi Anjo Kosei Hospital)
Akita, Hidetoshi (Department of Urology, JA Aichi Anjo Kosei Hospital)
Hashimoto, Yoshihiro (Department of Urology, JA Aichi Toyota Kosei Hospital)
Iwase, Yutaka (Department of Urology, JA Aichi Toyota Kosei Hospital)
Naiki, Taku (Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences)
Kawai, Noriyasu (Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences)
Tozawa, Keiichi (Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences)
Kohri, Kenjiro (Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.9, 2012 , pp. 4357-4361 More about this Journal
Abstract
Objective: The guidelines on indications for prophylactic use of Bacille Calmette-Gu$\acute{e}$rin (BCG) against non-muscle-invasive bladder cancer (NMIBC) have changed over the years. In order to assess the impact on outcome, the present retrospective comparison of BCG efficacy by time period with Japanese patients was conducted. Patients and Methods: A total of 146 cases of NMIBC treated with BCG since February 1985 were retrospectively evaluated. All patients received 80 mg of BCG (Tokyo 172 strain) six to eight times a week for prophylactic use. Comparison was made among three historical groups (Group A: 1980's, 39 cases; Group B: 1990's, 61 cases; Group C: 2000's, 46 cases). Results: In total, recurrence was seen in 55 of the 146 cases (37.7%), and progression in 14 (9.6%), 1 patient dying of cancer. These overall results were similar to those outlined in previous reports. However, the outcomes of this time-period-based analysis indicated a tendency for a shorter time to recurrence in patients after 2000, although a log-rank test showed no significance (P=0.229). Seven of the cases featuring progression (i.e., half of all such cases) were among the 46 Group C patients (15.2%). Excluding these progressive cases, there was no significant difference among the remaining 132 patients in the three groups. Conclusion: This study results revealed a tendency for a lower non-recurrence rate after 2000 in our series. This could stem from a number of factors, including changes in BCG indication criteria and the evolution of histopathological diagnostic criteria.
Keywords
Bacille Calmette-Gu$\acute{e}$rin; non-muscle-invasive bladder cancer; time period; Japanese patients;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hinotsu S,Akaza H, Isaka S, et al (2006). BCG Tokyo 172 Strain Study Group. Sustained prophylactic effect of intravesical bacille Calmette-Guerin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology, 67, 545-49.   DOI
2 Hinotsu S, Akaza H, Naito S, et al (2011). Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscleinvasive bladder cancer. BJU Int, 108,187-95.   DOI
3 http://www.auanet.org/content/clinical-practice-guidelines/ clinical-guidelines.cfm?sub=bc
4 http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf
5 http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR %20March %20 13th%2020 12.pelf
6 Irie A, Lee KE, Kadowaki K, et al (1994). Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence. Acta Urol Jpn, 40, 873-77.
7 Irie A, Uchida T, Yamashita H, et al (2003). Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette- Guerinfor superficial bladder cancer recmrence. Int J Urol, 10 ,183-89.   DOI
8 Joudi FN, Smith BJ, O'Donnell MA, et al (2006). The impact of age on the resJXlnse of patients with superficial bladder cancer to intravesical immunotherapy. J Urol, 175,1634-640.   DOI
9 Kano M, Kanemura M, Yokoyama M (1993). Risk factor of tumor recurrence following intravesical instillation of bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. Ann Soc BCG BRM Imm, 17, 39-44.
10 Kikuchi E, Fujimoto H, Mizutani Y, et al (2009). Cancer Registration Committee of the Japanese Urological Association. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Int J Urol, 16, 279-86.   DOI
11 Kohjimoto Y, Iba A, Shintani Y, et al (2010). Impact of Patient Age on Outcome Following Bladder-Preserving Treatment for Non-Muscle-Invasive Bladder Cancer. World J Urol, 28,425-30.   DOI
12 Librenjak D, Situm M, Vrdoljak E, et al (2012). Results of longterm follow- up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations. Urol Oncol, B, 259-65.
13 Margel D, Tal R, Golan S, et al (2007). Long-term follow-up of patients with stage T1 high grade transitional cell carcinoma managed by bacillus Calmette-Guerin immunotherapy. Urology , 69, 78-2.   DOI
14 Margel D, Alkhateeb SS, Finelli A, et al (2011). Diminished Efficacy of Bacille Cahnette-GuerinAmong Elderly Patients with Nonmuscle Invasive Bladder Cancer. Urology, 78, 848-55.   DOI
15 Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al (2005). Has a 3-fold decreased dose of Bacillus Cahnette-Guerin the same efficacy against recurrences and progression ofT 1 G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol, 174, 1242-47.   DOI
16 Meijer RP, van Rhijn BW (2012). A plea for long-term surveillance in bacillus Calmette-Guerin-treated nonmuscle- invasive bladder cancer. Eur Urol, 61, 508-09.   DOI
17 Oosterlinck W, Lobel B, Jackse G, et al (2001). EAU Recommendations 2001. "Guidelines on bladder cancer".
18 Ojea A, Nogueira JL, Solsona E, et al (2007). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol, 52,1398-406.   DOI   ScienceOn
19 Okamura T, Tozawa K, Yamada Y, et al (1996). Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing the recurrence of initially resistant superficial bladder cancers. J Urol, 156, 967-969.   DOI
20 Okamma T, Akita H, Hashimoto Y, et al (2010). Non Muscle Invasive Bladder Cancer Cases Initially Failing to Respond to Bacillus Calmette-Guerin Intravesical Instillation Therapy. Curr Urol, 4, 18-24.   DOI
21 Ozono S, Tabata S, Kaneko Y, et al (1992). Outcomes of intravesical instillation of bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. Ann Soc BCG BRM Imm, 16, 79-83.
22 Ozono S, Takashima K, Yoshida K, et al (1997). Intravesical bacillus Calmette-Guerin (BCG) therapy for prophylaxis of the superficial bladder cancer -Outcomes of randomized study-. Ann Soc BCG BRM Imm, 21, 87-91.
23 Segal R, Yafi FA, Brimo F, et al (2012). Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int, 109, 1026-1030.   DOI
24 Segawa N, Inamoto T, Nomi H, et al (2009). Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer. Acta Urol Jpn, 55,175-80.
25 Tachibana M, Nakamura S, Jitsukawa S, et al (1993). Long-term results and risk factors of tumor recurrence in patients with superficial bladder cancer who were treated by intravesical bacillus Calmette-Guerin (BCG) instillation. Jpn J Urol, 84, 656-661.   DOI
26 Smith JA Jr, Labasky RF, Cockett AT, et al (1999). Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol, 162, 1697-701.   DOI
27 Sylvester RJ (2011). Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer. Int J Urol, 18, 113-20.   DOI
28 Tachibana M, Jitsukawa S, Iigaya T, et al (1989). Comparative study on prophylactic intravesical instillation of bacillus Calmette-Guerin (BCG) and adriamycin for superficial bladder cancers. Jpn J Urol, 80, 1459-65.   DOI
29 Takashi M, Wakai K, Ohno Y, et al (1995). Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol and Nephrol, 27, 723-733.   DOI
30 Tanaka T, Shinoda M, Maruyama T, et al (1994). The 25 cases of tumor recurrence after intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Ann Soc BCG BRM Imm, 18, 95-100.
31 Thomas F, Rosario DJ, Rubin N, et al (2012). The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer-Time to change treatment paradigm? Cancer online, 27th April.   DOI
32 Tozawa K, Okamura T, Sasaki S, et al (2001). Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin is not indicated for superficial bladder cancer. Urol lnt, 67, 289-292.
33 Bladder cancer practice guideline : Japanese Urological Association (2009).
34 Yabusaki N, Komatsu H, Tago K, et al (1991). Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin. Jpn J Urol, 82, 290-296.   DOI
35 Yamamoto T, Hagiwara M, Nakazono M, et al (1990). Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect. Jpn J Urol, 81, 997-1001.   DOI
36 Yoneyama T, Ohyama C, Imai A, et al (2008). Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology, 71,1161-1165.   DOI
37 Ao T, Uchida T, Yokoyama E, et al (1993). Prophylactic combination therapy afterTUR of superficial bladder cancer. Acta Urol Jpn, 39, 987-91.
38 Ao T, Uchida T, Muramoto M, et al (1996). Postoperative intravesical pirarubicin plus bacillus Calmette-Guerin with or without interleukin-2 instillation therapy for superficial bladder cancer. Nishinihon J Urol, 5, 538-41.
39 Brausi M, Witjes JA, LammD, et al (2011). A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group. J Urol, 186, 2158-167   DOI
40 Cho IC, Kim EK, Joung JY, et al (2012). Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea. Anticancer Res, 32, 1493-98.